REPL
Replimune Group, Inc.
$8.88
+3.02%
$733.2M
No data for this timeframe.
Vol
Market Cap$733.2M
Cap SizeSmall Cap
Analyst ConsensusSell (8%)
Inst. Holders50 funds
Inst. Value$403.1M
Inst. Activity5 buys / 7 sells
Insider Activity0B / 8S
Insider Net $-$637.1K
Reddit Sentiment38° Cool
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001737953·Prev Close $8.62
Recent Activity
Jun 11, 2026
SEC
In Q3 2025, four mega-passive institutions (Fidelity, Morgan Stanley, Invesco, UBS) increased their REPL holdings by a n
INST-CLUSTER — Impact 4/10
Jun 1, 2026
Insider
Sarchi Christopher sold 12,000 shares
Chief Commercial Officer @ $9.24 ($110.9K)
May 31, 2026
Press
Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in hea
Impact 6/10
May 31, 2026
fda
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
<p>WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinica
May 30, 2026
Press
Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti-PD-1-faile
Impact 8/10
May 29, 2026
SEC
Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in comb
8-K — Impact 7/10
May 20, 2026
SEC
Three REPL insiders (CEO, CFO, and a director) sold a total of $319K in open-market sales on May 18, 2026, all at $5.08
CLUSTER — Impact 4/10
May 18, 2026
Insider
Hill Emily Luisa sold 7,812 shares
Chief Financial Officer @ $5.08 ($39.7K)
Price Targets
$4.67
-47.4% upside
Strong Sell
Current $8.88
Low $1.00
Median $4.00
High $9.00
6 analysts
$1.00
$9.00
Analyst Ratings
1Strong Buy
0Buy
7Hold
3Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | Wedbush | MAINTAIN | Neutral → Neutral |
| Apr 13, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight → Neutral |
| Apr 13, 2026 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Apr 13, 2026 | JP Morgan | DOWNGRADE | Neutral → Underweight |
| Apr 13, 2026 | Wedbush | DOWNGRADE | Outperform → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.72 ▲ +1.1% | $-0.77 — $-0.66 | 12% YoY | 4 |
| Next Q | $-0.60 ▲ +1.0% | $-0.70 — $-0.54 | 37% YoY | 3 |
| Current FY | $-3.27 ▲ +0.7% | $-3.39 — $-3.01 | -7% YoY | 4 |
| Next FY | $-2.06 ▲ +0.9% | $-2.71 — $-1.31 | 37% YoY | 5 |
Latest Reports
BEARISH
INST-CLUSTER
4/10
In Q3 2025, four mega-passive institutions (Fidelity, Morgan Stanley, Invesco, UBS) increased their REPL holdings by a n
Jun 11, 2026
BULLISH
Press
6/10
Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in hea
May 31, 2026
BULLISH
8-K
7/10
Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in comb
May 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BAKER BROS. ADVISORS LP | $84.5M | — |
| RTW INVESTMENTS, LP | $56.3M | DOUBLED |
| BlackRock, Inc. | $47.7M | — |
| STATE STREET CORP | $28.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Sarchi Christopher | SELL | $110.9K |
| May 18, 2026 | Hill Emily | SELL | $39.7K |
| May 18, 2026 | Patel Sushil | SELL | $189.6K |
| May 18, 2026 | Astley-Sparke Philip | SELL | $89.7K |
| May 18, 2026 | Sarchi Christopher | SELL | $43.8K |
Reddit Sentiment
38°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $403.1M total value (52,802,147 shares) as of 2026-Q1. Top holders: BAKER, RTW, BlackRock,. Net selling activity: 7 institutions trimmed/exited vs 5 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 11,045,336 | $84.5M | 21.0% | — |
| 2 | RTW INVESTMENTS, LP | 7,356,916 | $56.3M | 14.0% | DOUBLED +209.7% |
| 3 | BlackRock, Inc. | 6,239,239 | $47.7M | 11.8% | — |
| 4 | STATE STREET CORP | 3,782,237 | $28.9M | 7.2% | ADD +26.3% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,759,120 | $21.1M | 5.2% | — |
| 6 | D. E. Shaw & Co., Inc. | 2,336,528 | $17.9M | 4.4% | DOUBLED +538.2% |
| 7 | GOLDMAN SACHS GROUP INC | 2,277,276 | $17.4M | 4.3% | — |
| 8 | FMR LLC | 2,045,490 | $15.6M | 3.9% | TRIM -31.4% |
| 9 | Erste Asset Management GmbH | 2,120,000 | $15.3M | 3.8% | ADD +30.1% |
| 10 | TORONTO DOMINION BANK | 1,591,030 | $12.2M | 3.0% | TRIM -28.6% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,301,600 | $10.0M | 2.5% | — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 1,140,099 | $8.7M | 2.2% | — |
| 13 | MORGAN STANLEY | 646,213 | $4.9M | 1.2% | TRIM -40.8% |
| 14 | TUDOR INVESTMENT CORP ET AL | 631,900 | $4.8M | 1.2% | DOUBLED +518.3% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 623,979 | $4.8M | 1.2% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 611,759 | $4.7M | 1.2% | — |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 552,576 | $4.2M | 1.0% | — |
| 18 | VANGUARD FIDUCIARY TRUST CO | 475,126 | $3.6M | 0.9% | — |
| 19 | CITADEL ADVISORS LLC | 398,729 | $3.1M | 0.8% | TRIM -56.7% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 395,300 | $3.0M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 2,981,580 | 2,045,490 | -31.4% | $15.6M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 2,229,527 | 1,591,030 | -28.6% | $12.2M | 2026-Q1 |
| Woodline Partners LP | TRIM | 570,988 | 380,988 | -33.3% | $2.9M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEAR_EXIT | 1,807,368 | 307,368 | -83.0% | $2.4M | 2026-Q1 |
| Invesco Ltd. | TRIM | 613,015 | 190,925 | -68.9% | $1.5M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 41,181 | 52,407 | +27.3% | $400.9K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 52,961 | 35,893 | -32.2% | $274.6K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 8,121 | 31,492 | +287.8% | $240.9K | 2026-Q1 |
| CWM, LLC | DOUBLED | 4,047 | 12,409 | +206.6% | $94.9K | 2026-Q1 |
| Allworth Financial LP | ADD | 3,899 | 5,257 | +34.8% | $40.2K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 121 | 2,141 | +1669.4% | $16.4K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 20,952 | 34 | -99.8% | $260.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 2,924,125 | 3,693,107 | +26.3% | $35.9M | 2025-Q4 |
| FMR LLC | DOUBLED | 1,361,079 | 2,981,580 | +119.1% | $29.0M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 403,495 | 2,575,042 | +538.2% | $25.0M | 2025-Q4 |
| TORONTO DOMINION BANK | ADD | 1,372,052 | 2,229,527 | +62.5% | $21.7M | 2025-Q4 |
| Erste Asset Management GmbH | ADD | 1,630,000 | 2,120,000 | +30.1% | $20.6M | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,807,368 | — | $17.6M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,375,519 | 814,888 | -40.8% | $7.9M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 154,301 | 613,015 | +297.3% | $6.0M | 2025-Q4 |
| Woodline Partners LP | TRIM | 855,988 | 570,988 | -33.3% | $5.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 157,499 | 444,074 | +182.0% | $4.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 109,284 | 215,330 | +97.0% | $2.1M | 2025-Q4 |
| Rafferty Asset Management, LLC | ADD | 108,592 | 140,909 | +29.8% | $1.4M | 2025-Q4 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 20,765 | 128,380 | +518.3% | $1.2M | 2025-Q4 |
14 unique insiders with 29 transactions. Net insider value: -$637.1K ($0.00 bought, $637.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sarchi Christopher | Chief Commercial Officer | SELL | 12,000 | $9.24 | $110.9K |
| May 18, 2026 | Hill Emily Luisa | Chief Financial Officer | SELL | 7,812 | $5.08 | $39.7K |
| May 18, 2026 | Patel Sushil | Chief Executive Officer | SELL | 37,324 | $5.08 | $189.6K |
| May 18, 2026 | Astley-Sparke Philip | Director | SELL | 17,657 | $5.08 | $89.7K |
| May 18, 2026 | Sarchi Christopher | Chief Commercial Officer | SELL | 8,626 | $5.08 | $43.8K |
| May 18, 2026 | Schwendenman Andrew | Chief Accounting Officer | SELL | 7,894 | $5.08 | $40.1K |
| May 18, 2026 | Xynos Konstantinos | Chief Medical Officer | SELL | 14,023 | $5.08 | $71.2K |
| Apr 2, 2026 | Sarchi Christopher | Chief Commercial Officer | SELL | 6,500 | $8.01 | $52.1K |
| Apr 1, 2026 | Weinand Dieter | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Peeples-Dyer Veleka | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Hill Emily Luisa | Chief Financial Officer | AWARD | 50,000 | — | — |
| Apr 1, 2026 | Hill Emily Luisa | Chief Financial Officer | AWARD | 75,000 | — | — |
| Apr 1, 2026 | SLATTERY JOSEPH P | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Pucci Paolo | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Dhingra Kapil | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Patel Sushil | Chief Executive Officer | AWARD | 251,240 | — | — |
| Apr 1, 2026 | Patel Sushil | Chief Executive Officer | AWARD | 376,860 | — | — |
| Apr 1, 2026 | Schwendenman Andrew | Chief Accounting Officer | AWARD | 36,667 | — | — |
| Apr 1, 2026 | Oliger Christy J. | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Astley-Sparke Philip | Director | AWARD | 50,000 | — | — |
| Apr 1, 2026 | Schwendenman Andrew | Chief Accounting Officer | AWARD | 55,000 | — | — |
| Apr 1, 2026 | Balachandran Madhavan | Director | AWARD | 44,500 | — | — |
| Apr 1, 2026 | Xynos Konstantinos | Chief Medical Officer | AWARD | 50,000 | — | — |
| Apr 1, 2026 | Xynos Konstantinos | Chief Medical Officer | AWARD | 75,000 | — | — |
| Apr 1, 2026 | Astley-Sparke Philip | Director | AWARD | 75,000 | — | — |
| Apr 1, 2026 | Sarchi Christopher | Chief Commercial Officer | AWARD | 50,000 | — | — |
| Apr 1, 2026 | Sarchi Christopher | Chief Commercial Officer | AWARD | 75,000 | — | — |
| Apr 1, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 44,500 | — | — |
| Feb 18, 2026 | Astley-Sparke Philip | Director | GIFT | 25,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
INST-CLUSTER
4/10
In Q3 2025, four mega-passive institutions (Fidelity, Morgan Stanley, Invesco, UBS) increased their
Jun 11, 2026
BULLISH
8-K
7/10
Replimune announced it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene o
May 29, 2026
NEUTRAL
CLUSTER
4/10
Three REPL insiders (CEO, CFO, and a director) sold a total of $319K in open-market sales on May 18,
May 20, 2026
BULLISH
6/10
Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing dura
May 31, 2026
BULLISH
8/10
Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivoluma
May 30, 2026
BULLISH
8/10
Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for adv
May 29, 2026
Current analyst consensus: Strong Sell (8% buy). Based on 13 analysts: 1 strong buy, 0 buy, 7 hold, 3 sell, 2 strong sell.
Analyst Price Targets
$4.67 mean target
-47.4% upside
Strong Sell (3.50)
$1.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $8.88 |
| Target Low | $1.00 |
| Target Mean | $4.67 |
| Target Median | $4.00 |
| Target High | $9.00 |
| # Analysts | 6 |
| Recommendation | Strong Sell (3.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.72 | $-0.77 | $-0.66 | 12.2% | +1.1% | — | $0.0B | 0.0% | 4 |
| Next Q 2026-06-30 |
$-0.60 | $-0.70 | $-0.54 | 37.2% | +1.0% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-03-31 |
$-3.27 | $-3.39 | $-3.01 | -6.7% | +0.7% | — | $0.0B | 0.0% | 4 |
| Next FY 2027-03-31 |
$-2.06 | $-2.71 | $-1.31 | 37.0% | +0.9% | 1↑ 0↓ | $0.0B | -11.1% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.720 | |
| 7d ago | $-0.728 | +0.008 |
| 30d ago | $-0.728 | +0.008 |
| 60d ago | $-0.768 | +0.048 |
| 90d ago | $-0.768 | +0.048 |
7 analyst firms have rated this stock: 0 upgrades, 6 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 13, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Apr 13, 2026 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Apr 13, 2026 | JP Morgan | DOWNGRADE | Neutral | Underweight |
| Apr 13, 2026 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Apr 13, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Apr 13, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Sell |
| Feb 5, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 4, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 0 | 7 | 3 | 2 | 8% | |
| May 1, 2026 | 1 | 0 | 6 | 4 | 2 | 8% | |
| Apr 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
38°
Cool
Bearish
Neutral
Bullish
4 mentions
0 bullish
2 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 13, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 31, 2026
fda
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
<p>WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the devel
May 30, 2026
fda
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
<p>WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the devel
May 29, 2026
fda
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
<p>WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the devel
May 20, 2026
earnings_calendar
REPL Q4 2026 Earnings After Market Close — 2026-05-20
Apr 13, 2026
short_interest
FTD: REPL — 175,001 shares ($0.8M) failed to deliver
Settlement: 20260413, Price: $4.76, FTD Value: $833,004.76, REPLIMUNE GROUP INC COM (DE)
Apr 10, 2026
fda
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
<p>WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the dev
Apr 10, 2026
fda_pdufa
PDUFA: REPL — RP1 in Anti-PD-1 failed melanoma — 2026-04-10
FDA target action date 2026-04-10 for REPL (Replimune Group, Inc.). Drug: RP1. Indication: Anti-PD-1 failed melanoma. PDUFA target action date of Apri
Apr 8, 2026
short_volume
Short Volume: REPL — 61.5% short (1.7M / 2.7M)
Short: 1,671,433 | Exempt: 111,593 | TRF Vol: 2,719,471 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: REPL — 68.1% short (0.9M / 1.4M)
Short: 944,056 | Exempt: 3,124 | TRF Vol: 1,385,367 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: REPL — 69.0% short (0.9M / 1.3M)
Short: 888,013 | Exempt: 900 | TRF Vol: 1,286,304 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: REPL — 59.0% short (0.9M / 1.6M)
Short: 948,745 | Exempt: 4,617 | TRF Vol: 1,606,847 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_interest
FTD: REPL — 247,866 shares ($1.9M) failed to deliver
Settlement: 20260401, Price: $7.65, FTD Value: $1,896,174.9, REPLIMUNE GROUP INC COM (DE)